25
total announcements
MOREPENLAB.BO · 15 min delayed
Key Stats · Yahoo Finance · as of 22 Oct 2026
Market Cap
₹6,345 Cr
P/E (TTM)
64.7
EPS (TTM)
₹1.79
52W Low
₹33.47
52W High
₹123.40
Dividend Yield
0.51%
Beta
0.54
Price / Book
5.3
Return on Equity
8.62%
Debt / Equity
13.2
Revenue (TTM)
₹1,756 Cr
Gross Margin
33.88%
Operating Margin
5.78%
Morepen Laboratories Ltd
Morepen Laboratories Ltd has scheduled a Board Meeting on 27/10/2026 to consider and approve financial results for the quarter and half year ended 30 September 2026.
Morepen Laboratories Ltd
Morepen Laboratories Ltd has received a favorable judgment from the Hon'ble High Court of Himachal Pradesh at Shimla, quashing a Show Cause Notice (SCN) issued by the Office of the Commissioner, Central GST & Central Excise Commissionerate, Shimla, seeking recovery of ₹117,94,03,452/- towards excess GST refund, along with applicable interest and penalty.
Morepen Laboratories Ltd
Morepen Laboratories Ltd has closed its trading window from 1st October 2026 to announce unaudited consolidated and standalone financial results for the quarter and half year ended on 30th September 2026.
Morepen Laboratories Ltd
Morepen Laboratories Ltd has submitted its first U.S. ANDA for Sitagliptin Tablets USP in three strengths, strengthening its integrated CDMO capabilities and expanding its API-to-finished dosage development offering.
Morepen Laboratories Ltd
Morepen Laboratories Ltd has announced the voting results and scrutinizer report of its 41st Annual General Meeting (AGM) held on September 26, 2026, through video conferencing. The company provided e-voting facility to its members, and the results are available on its website and NSDL's website.
Morepen Laboratories Ltd
Morepen Laboratories Ltd held its 41st Annual General Meeting on September 26, 2026, through video conferencing. The meeting approved the audited financial statements for the year ended March 31, 2026, and declared a final dividend of ₹0.20 per equity share. Other resolutions, including the appointment of a director and the elevation of Mr. Sanjay Suri to Managing Director, were also approved.
Morepen Laboratories Ltd
Morepen Laboratories Ltd has received an ESG rating of 'CRISIL ESG 60' from CRISIL, indicating an 'Adequate' rating category. The rating is based on publicly disclosed information for fiscal 2026.
Morepen Laboratories Ltd
Morepen Laboratories Ltd has published a newspaper notice for the completion of dispatch of the notice of its 41st Annual General Meeting and the Annual Report for the financial year 2025-26.
Morepen Laboratories Ltd
Morepen Laboratories Ltd has dispatched letters to unregistered members with a weblink to access the Annual Report for 2025-26. The company has also announced the 41st AGM on September 26, 2026, and proposed a final dividend of ₹ 0.20 per equity share.
Morepen Laboratories Ltd
Morepen Laboratories Ltd has released its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, as per SEBI regulations.
Morepen Laboratories Ltd
Morepen Laboratories Ltd has announced the notice of its 41st Annual General Meeting (AGM) to be held on September 26, 2026, through video conferencing. The AGM will consider the adoption of financial statements, declaration of final dividend, appointment of a director, and other business.
Morepen Laboratories Ltd
Morepen Laboratories Ltd has released its Annual Report for the financial year 2025-26, along with the notice of its 41st Annual General Meeting scheduled for September 26, 2026.
Morepen Laboratories Ltd
Morepen Laboratories Ltd has published a newspaper notice regarding its 41st Annual General Meeting, dividend, and record date. The notice is in accordance with Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company's website has the notice available for public access.
Morepen Laboratories Ltd
Morepen Laboratories Ltd has informed that its wholly owned subsidiary, Morepen RX Limited, has allotted 2,00,00,000 equity shares to the company at par, aggregating to Rs. 20,00,00,000, to strengthen its capital base and support its business operations.
Morepen Laboratories Ltd
Morepen Laboratories Ltd has published its un-audited standalone and consolidated financial results for the quarter ended June 30, 2026, which were approved by the Board of Directors on August 4, 2026. The results are available on the company's website and have been published in the Financial Express (English) and Jansatta (Hindi) newspapers on August 5, 2026.
Morepen Laboratories Ltd
Morepen Laboratories Ltd has released a monitoring agency report for the quarter ended June 30, 2026, as per SEBI regulations, detailing the utilization of proceeds from its qualified institutions placement issue.
Morepen Laboratories Ltd
Morepen Laboratories Ltd has announced the outcome of its Board meeting, which includes the approval of un-audited standalone and consolidated financial results for the quarter ended June 30, 2026, and the record date for the final dividend for the financial year ended March 31, 2026. The company has also announced the re-appointment of Mr. Sushil Suri as the Chairman & Managing Director for a further period of three years, subject to member approval at the 41st Annual General Meeting on September 26, 2026.
Morepen Laboratories Ltd
The Board of Directors of Morepen Laboratories Ltd has approved the re-appointment of Mr. Sushil Suri as Chairman & Managing Director for a further period of three years, effective from October 20, 2026. The company has also announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, and has fixed a record date for the final dividend for the financial year ended March 31, 2026. Additionally, the company has sought approval from its members for the extension of the approved timeline for hiving off its Medical Devices Business into a subsidiary company.
Morepen Laboratories Ltd
Morepen Laboratories Ltd has announced the record date for payment of final dividend for the financial year ended 31st March 2026, subject to approval at the 41st Annual General Meeting. The company has also approved the re-appointment of Mr. Sushil Suri as Chairman & Managing Director for a further period of three years. Additionally, the company has announced the notice of the 41st AGM to be held on 26th September 2026.
Morepen Laboratories Ltd
Morepen Laboratories Ltd reported its highest-ever quarterly revenue and earnings in Q1 FY27, with EBITDA growing by 207% and PAT by 394%. The company's CDMO mandate entered full scale commercialization phase, with Rs. 58 Cr worth of commercial CDMO dispatches already completed during the quarter.